A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
The number of children in temporary accommodation has increased at a rate the equivalent of an extra secondary school of pupils a month.
The high street chemist - which charges almost £15 more for the pill than rivals - said it was "truly sorry" for a "poor choice of words".
The head of Minneapolis police stood down at the city mayor's request after the police killing of bride-to-be Justine Damond.